No.
|
Strain
|
Pathway Deficiency
|
Medium M9
|
M9 + NA
|
M9 + NAD+
|
M9 + NAM
|
---|
Expected
|
Observed
|
Expected
|
Observed
|
Expected
|
Observed
|
Expected
|
Observed
|
---|
1
|
BW25113
|
None
|
+
|
65.8
|
+
|
49.8
|
+
|
50.5
|
+
|
49.4
|
2
|
ΔnadC
|
dn
|
–
|
–
|
+
|
49.4
|
+
|
49.4
|
+
|
53.4
|
3
|
ΔnadC ΔpncA
|
dn, I
|
–
|
–
|
+
|
50.3
|
+
|
49.2
|
–
|
380.8
|
4
|
ΔnadC ΔpncA ΔxapA
|
dn, I
|
–
|
–
|
+
|
49.2
|
+
|
50.0
|
–
|
620.4
|
5
|
ΔnadC ΔpncA ΔxapA/pBAD-xapA
|
dn, I
|
–
|
NT
|
+
|
NT
|
+
|
+
|
–
|
376.4
|
6
|
ΔnadC ΔpncA ΔxapA/pBAD-EGFP
|
dn, I
|
–
|
NT
|
+
|
NT
|
+
|
+
|
–
|
626.8
|
7
|
ΔnadC ΔpncA ΔnadR
|
dn, I, III
|
–
|
–
|
+
|
51.1
|
+
|
NT
|
–
|
–
|
8
|
ΔnadC ΔpncA ΔxapA ΔnadR
|
dn, I, III
|
–
|
–
|
+
|
49.7
|
+
|
NT
|
–
|
–
|
- *Notes: NA, nicotinic acid; NAM, nicotinamide; NAD+, nicotinamide adenine dinucleotide; NT, not tested; –, No proliferation; +, proliferation; dn, de novo NAD+ synthesis; I, NAD+ salvage pathway I; III, NAD+ salvage pathway III.